ATE275421T1 - Interleukin-12 und herpes simplex virusantigen enthaltende impfstoffe - Google Patents

Interleukin-12 und herpes simplex virusantigen enthaltende impfstoffe

Info

Publication number
ATE275421T1
ATE275421T1 AT99905946T AT99905946T ATE275421T1 AT E275421 T1 ATE275421 T1 AT E275421T1 AT 99905946 T AT99905946 T AT 99905946T AT 99905946 T AT99905946 T AT 99905946T AT E275421 T1 ATE275421 T1 AT E275421T1
Authority
AT
Austria
Prior art keywords
herpes simplex
simplex virus
virus antigen
vaccines containing
containing interleukin
Prior art date
Application number
AT99905946T
Other languages
English (en)
Inventor
Eric M Mishkin
John H Eldridge
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE275421T1 publication Critical patent/ATE275421T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT99905946T 1998-02-12 1999-02-10 Interleukin-12 und herpes simplex virusantigen enthaltende impfstoffe ATE275421T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7450398P 1998-02-12 1998-02-12
PCT/US1999/002923 WO1999040938A2 (en) 1998-02-12 1999-02-10 Vaccines comprising interleukin-12 and herpes simplex viral antigen

Publications (1)

Publication Number Publication Date
ATE275421T1 true ATE275421T1 (de) 2004-09-15

Family

ID=22119907

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99905946T ATE275421T1 (de) 1998-02-12 1999-02-10 Interleukin-12 und herpes simplex virusantigen enthaltende impfstoffe

Country Status (15)

Country Link
US (1) US6488936B1 (de)
EP (1) EP1053017B1 (de)
JP (1) JP2002502884A (de)
KR (1) KR100622716B1 (de)
CN (1) CN1224422C (de)
AT (1) ATE275421T1 (de)
AU (1) AU764036B2 (de)
BR (1) BR9907883A (de)
CA (1) CA2320041A1 (de)
DE (1) DE69919984T2 (de)
DK (1) DK1053017T3 (de)
ES (1) ES2226338T3 (de)
IL (1) IL137811A (de)
PT (1) PT1053017E (de)
WO (1) WO1999040938A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200103266T2 (tr) * 1999-05-13 2002-01-21 American Cyanamid Company Yardımcı kombinasyon formülasyonları
CN1222619C (zh) * 1999-12-17 2005-10-12 惠氏控股公司 增强对单纯疱疹病毒疫苗应答的疫苗及其制药应用
EP1337149A4 (de) 2000-10-27 2005-10-12 Irx Therapeutics Inc Vakzinimmuntherapie für immungeschwächte patienten
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
HRP20030355A2 (en) * 2000-11-10 2005-04-30 Wyeth Holdings Corporation Adjuvant combination formulations
US6867000B2 (en) 2000-12-07 2005-03-15 Wyeth Holdings Corporation Method of enhancing immune responses to herpes
JP2004099584A (ja) 2002-05-02 2004-04-02 Keio Gijuku Ｈｓｖを用いた抗腫瘍剤
CN1301749C (zh) * 2005-12-09 2007-02-28 复旦大学 抗单纯疱疹病毒－2感染的多表位dna疫苗及其制备方法
US7790203B2 (en) * 2005-12-13 2010-09-07 Lowder Tom R Composition and regimen for the treatment of herpes simplex virus, herpes zoster, and herpes genitalia epidermal herpetic lesions
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
EP3403667B1 (de) 2006-09-26 2020-07-22 Infectious Disease Research Institute Impfstoffzusammensetzung mit einem synthetischen adjuvans
AU2010248761B2 (en) 2009-05-15 2016-02-11 Irx Therapeutics, Inc. Vaccine immunotherapy
SI2437753T1 (sl) 2009-06-05 2016-12-30 Infectious Disease Research Institute Sintetični glukopiranozil-lipidni adjuvansi in cepivni sestavki, ki jih vsebujejo
WO2011056650A2 (en) 2009-10-27 2011-05-12 Michael Zasloff Methods and compositions for treating and preventing viral infections
US9333238B2 (en) 2009-12-08 2016-05-10 Irx Therapeutics, Inc. Method of immunotherapy for treament of human papillomavirus infection
BR112013025799A2 (pt) 2011-04-08 2016-12-20 Immune Design Corp método para induzir uma resposta imune em um sujeito, e, preparação
EP2850431B1 (de) 2012-05-16 2018-04-18 Immune Design Corp. Impfstoffe gegen hsv-2
JP6426706B2 (ja) 2013-04-18 2018-11-21 イミューン デザイン コーポレイション がん処置で使用するためのｇｌａ単剤療法
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
EP3454878A4 (de) 2016-05-10 2020-07-29 Hennepin Healthcare Research Institute Zytokinsignalisierende immunmodulatoren und verfahren

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022473A1 (en) * 1993-04-01 1994-10-13 University Of Washington Use of interleukin 7 to improve vaccine potency
US5571515A (en) * 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
IL114576A0 (en) * 1994-07-22 1995-11-27 Merck & Co Inc Polynucleotide herpes virus vaccine
GB9422990D0 (en) * 1994-11-15 1995-01-04 Cortecs Ltd Immunogenic compositions
WO1998008947A1 (en) * 1995-12-19 1998-03-05 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Enhancement of dna immunization through the use of cytokines

Also Published As

Publication number Publication date
DE69919984T2 (de) 2005-11-17
CN1224422C (zh) 2005-10-26
BR9907883A (pt) 2000-11-14
AU764036B2 (en) 2003-08-07
JP2002502884A (ja) 2002-01-29
ES2226338T3 (es) 2005-03-16
DK1053017T3 (da) 2004-11-22
IL137811A (en) 2005-12-18
DE69919984D1 (de) 2004-10-14
EP1053017B1 (de) 2004-09-08
KR20010040867A (ko) 2001-05-15
WO1999040938A3 (en) 2000-08-24
PT1053017E (pt) 2004-12-31
IL137811A0 (en) 2001-10-31
US6488936B1 (en) 2002-12-03
CA2320041A1 (en) 1999-08-19
WO1999040938A2 (en) 1999-08-19
AU2598199A (en) 1999-08-30
EP1053017A2 (de) 2000-11-22
KR100622716B1 (ko) 2006-09-13
CN1299287A (zh) 2001-06-13

Similar Documents

Publication Publication Date Title
ATE275421T1 (de) Interleukin-12 und herpes simplex virusantigen enthaltende impfstoffe
WO1999040936A3 (en) Pneumococcal and meningococcal vaccines formulated with interleukin-12
AU7980794A (en) Methods and compositions for microencapsulation of antigens for use as vaccines
FI920132A0 (fi) Stabila vaccinkompositioner innehaollande interleukiner.
CA2185470A1 (en) Compositions and methods for vaccines comprising .alpha.-galactosyl epitopes
ES2186809T3 (es) Composiciones de vacunas para administracion intranasal, comprendiendo chitosana y su uso.
ATE454163T1 (de) Bakterielle impfstoffe, enthaltend auxotrophe attenuierte listerienstämme, welche heterologe antigene exprimieren
MX9801638A (es) Compuestos y metodos para inmunoterapia y diagnostico de tuberculosis.
ATE397942T1 (de) Adjuvanszusammensetzungen zur erhöhung der immunantwort bezüglich polynukleotid-basierenden impfstoffen
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
IL150602A0 (en) Proteosome influenza vaccine
MY150893A (en) Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
CA2437201A1 (en) Methods and compositions useful for stimulating an immune response
IL130075A0 (en) A vaccine for eliciting an immune response to an antigen in an animal
PT939648E (pt) Formulações de vacinas de rotavírus
WO1999040937A3 (en) Vaccines comprising interleukin-12 and respiratory syncytial viral antigens
WO2005012538A3 (en) Accelerated vaccination
DE60220642D1 (de) Perylenequinone zur anwendung mit immunotherapeutischen mitteln
GB9818133D0 (en) Vaccine
DE60131975D1 (de) Anwendung des herpes simplex virus glykoproteins-d zur unterdrückung von immunantworten
WO2001035993A3 (en) Compositions and methods for stimulating an immune response against infectious agents
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung
DE69830156D1 (de) Zusammensetzungen zur immunverstärkung von impfstoffen
ES2091159A1 (es) Antigeno recombinante, rsm14, procedente de schistosoma mansoni, su obtencion y utilizacion.
EP1027895A3 (de) Erysipelothrix rhusiopathiae Antigene und Impfstoff-Zusammensetzungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1053017

Country of ref document: EP

REN Ceased due to non-payment of the annual fee